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AbstrAct
Objective to compare the characteristics of patients 
with psoriatic arthritis among patient groups stratified by 
degree of skin and joint involvement, and to evaluate the 
relationship between skin severity and joint activity.
Methods Body surface area (BSa) and clinical Disease 
activity index (cDai) at enrolment were analysed. Patient 
characteristics were stratified by skin severity and joint 
activity. Baseline patient characteristics, clinical and 
disease characteristics and patient-reported outcomes 
were compared. the strength of the relationship of skin 
severity and joint activity was evaluated using methods for 
categorical variables (χ2 test, cramer’s V) and continuous 
variables (linear regression).
Results 1542 adult patients in the corrona Psoriatic 
arthritis/Spondyloarthritis registry enrolled between 21 
May 2013 and 20 September 2016 were analysed. Most 
patients in the BSa >3%/cDai moderate/high subgroup 
had worse clinical and patient-reported outcomes. a 
significant (p<0.001) modest association (cramer’s 
V=0.1639) between skin severity and joint activity was 
observed among all patients at enrolment. Patients with 
higher skin severity were two times more likely to have 
higher joint involvement (Or 2.27, 95% ci 1.71 to 3.01). 
a significant linear relationship between cDai and BSa 
was observed. effect modification showed this linear 
relationship was modified by age, gender, insurance, 
work status, current therapy, Health assessment 
Questionnaire, nail visual analogue scale, minimal 
disease activity, dactylitis count, patient-reported pain 
and fatigue.
Conclusion Skin severity is modestly correlated with 
joint activity, and patients with higher skin severity are 
two times more likely to have increased joint involvement. 
clinicians need to address both skin severity and joint 
activity in treatment decisions.
InTROduCTIOn
Psoriatic arthritis (PsA) is a chronic, 
inflammatory condition that presents with 
cutaneous (involvement of skin and nails), 
musculoskeletal (arthritis, enthesitis, 
dactylitis and spondylitis) and extra-artic-
ular features (inflammatory bowel disease, 
uveitis).1–3 Psoriasis (PsO) affects up to 
3.2% of the population in the USA, and 
studies have found up to 30% of patients 
with PsO have PsA.4 5 Compared with the 
general population, patients with PsA have 
a lower health-related quality of life (QOL) 
and experience a higher risk of developing 
comorbidities including malignancy and 
cardiovascular disease. Previous studies of 
patients with PsA have shown that patients 
with skin involvement have a more signifi-
cant impairment of QOL measures and an 
Key messages
What is already known about this subject?
 ► limited information is known about the relationships 
between skin disease severity and joint disease ac-
tivity in patients with psoriatic arthritis (Psa).
 ► Studies examining the clinical characteristics of 
patients with Psa have not found consistent cor-
relations between baseline skin and joint disease 
measures.
What does this study add?
 ► Our study found the strength of the relationship be-
tween joint disease activity and skin disease severity 
was modest, yet statistically significant.
 ► Patients with higher skin disease severity (body sur-
face area (BSa) >3%) were two times more likely 
to have higher joint disease involvement compared 
with those with a BSa=0%.
How might this impact on clinical practice?
 ► clinicians (specifically rheumatologists and der-
matologists) need to approach Psa patient care 
comprehensively addressing both the skin disease 
severity and joint disease activity in the treatment 
of these patients.
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increase in overall comorbidities.6 7 Studies examining 
the clinical characteristics of patients with PsA have 
not found consistent correlations between baseline 
skin and joint disease measures.8–11 Determining the 
relationship between severity of skin disease and joint 
disease activity is important for better phenotyping 
of patients with both skin and joint involvement and 
can guide clinicians in management. The objectives 
of this study were to compare patient characteristics 
(demographics, comorbidities, symptoms and medica-
tions) at enrolment among patient groups defined by 
degree of skin and joint involvement, and to evaluate 
the relationship between the degree of skin and joint 
involvement.
MeTHOds
data source
The Corrona Registry is an independent, prospective, obser-
vational cohort of patients with PsA recruited at 40 private 
and academic practice sites across 25 states in the USA.12 As of 
31 March 2018, the Corrona Psoriatic Arthritis/Spondyloar-
thritis (PsA/SpA) Registry database included information 
on 2827 patients. Data on 11 525 patient visits and approxi-
mately 6278 patient-years of follow-up observation time had 
been collected. The mean time of patient follow-up was 3.1 
years (median, 3.5 years). Data were collected from both 
patients and their treating rheumatologists, who gathered 
information on disease duration, prognosis, disease severity 
and activity, medical comorbidities, use of medications 
including biologics, conventional synthetic disease-mod-
ifying antirheumatic drugs (csDMARD), prednisone and 
adverse events. Follow-up assessments were requested at 
least as often as every 6 months and completed during 
routine clinical encounters. The Corrona Registry was 
established in accordance with the Declaration of Helsinki. 
All participating investigators were required to obtain full 
board approval for conducting non-interventional research 
involving human subjects. Sponsor approval and continuing 
review were obtained through a central Institutional Review 
Board (IRB). For academic investigative sites that did not 
receive a waiver to use the central IRB, full board approval 
was obtained from the respective governing IRBs and docu-
mentation of approval was submitted to Corrona before 
initiating any study procedures. All registry patients were 
required to provide written informed consent and author-
isation before participating.
study population
Our study cohort included 1542 patients in the Corrona 
PsA/SpA Registry who were continuously enrolled 
following an index date defined as enrolment between 21 
March 2013 and 20 September 2016. Patients ≥18 years of 
age with a diagnosis of PsA and with a history of PsO at the 
time of enrolment into the Corrona PsA/SpA Registry were 
recruited for the study. Patients were further required to 
have available body surface area (BSA) and Clinical Disease 
Activity Index (CDAI) measurements at enrolment. BSA is 
usually measured by estimating the per cent body involve-
ment of PsO, and it ranges from 0% to 100%. One per cent 
BSA represents a one handprint size of the patient. The 
CDAI was developed to determine a patient’ s joint disease 
activity for rheumatoid arthritis but can also be used for 
PsA.13 The CDAI comprised four assessment tools: swollen 
(28) joint count, tender (28) joint count, Patient Global 
disease Activity and the Evaluator’s Global disease Activity 
indexes. A CDAI activity score of ≤2.8 is considered remis-
sion, a CDAI score >2.8 and ≤10 is low disease activity, a 
CDAI score >10 and ≤22 is moderate disease activity and a 
CDAI score >22 is high disease activity.14
For purposes of our study, patients with PsA were 
stratified by skin disease severity and joint disease 
activity determined at enrolment as follows: BSA 0% 
(history of PsO but not current/active); low (BSA >0% 
to ≤3%); and moderate-high (BSA >3%). Joint disease 
activity was measured by CDAI, where a CDAI ≤10 was 
low and a CDAI >10 was considered moderate-high. 
Patients were further divided into six subgroups: 
BSA 0%/CDAI low; BSA 0%/CDAI moderate-high; 
BSA >0% to ≤3%/CDAI low; BSA >0% to ≤3%/CDAI 
moderate-high; BSA >3%/CDAI low; and BSA >3%/
CDAI moderate-high. Demographic characteristics, 
duration of PsA, time since PsO diagnosis, clinical 
characteristics, patient-reported outcomes, history 
of PsA drug therapy and current PsA drug therapy at 
enrolment were also collected.
statistical analyses
comparison of baseline characteristics by skin disease severity 
and joint disease activity
Patient characteristics, including current and prior PsA 
medication use, were obtained during the enrolment visit 
and stratified by skin disease severity and joint disease 
activity. We compared baseline patient characteristics, 
clinical and disease characteristics and patient-reported 
factors among the six stratified skin disease severity-joint 
disease activity groups using appropriate methods: anal-
ysis of variance for continuous variables and χ2 test of 
association (for categorical variables; Fisher’s test used if 
a cell count had <5). Any comparison with a resulting 
p value <0.05 was flagged and considered in the list of 
factors used for evaluating the relationship between skin 
disease severity and joint disease activity.
evaluating the relationship between skin disease severity and joint 
disease activity and factors that modify the relationship
The overall relationship of skin disease severity evaluated 
by BSA and joint disease activity (evaluated by CDAI) 
levels was calculated using the χ2 test of association, 
and the strength of the relationship between these two 
variables was measured using Cramer’s V, which is the 
standard correlation of two categorical variables with two 
or more categories each. Cramer’s V is used in conjunc-
tion with a significant χ2 test to determine the strength of 
association. Cramer’s V ranges from 0 (no relationship) 
to 1 (strong relationship). Also, we calculated the OR 
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to estimate the risk of being in moderate or high joint 
disease activity among patients with severe skin severity 
compared with patients with low joint disease activity and 
no skin involvement (BSA=0).
To further evaluate whether other variables (chosen a 
priori or identified through significance testing) modified 
the relationship between CDAI and BSA, multiple linear 
regression was performed starting with the list of a priori vari-
ables (ie, age, gender, body mass index (BMI), work status, 
smoking status, duration of PsA, time since PsO diagnosis, 
prior biologic or targeted synthetic DMARD (tsDMARD) 
use, current biologics or tsDMARD use, prior csDMARD 
use, Spondyloarthritis Research Consortium of Canada 
(SPARCC) enthesitis and dactylitis count and minimal 
disease activity (MDA)), and each variable was included in 
a separate model of CDAI regressed onto BSA. Effect modi-
fication of each variable was evaluated by including an inter-
action term (BSA and the variable under evaluation) into 
the linear regression model and assessed for statistical signif-
icance with the likelihood ratio test p<0.05.
ResulTs
There were 1542 patients who met the inclusion criteria. 
The skin activity groups were categorised as follows: 
24% (0% BSA), 44% (low BSA) and 32% of patients 
had moderate/high BSA levels. The low CDAI group 
comprised 62% of all patients (table 1).
All patient demographic characteristics
The preponderance of patients were (52.9%) females. 
The mean age for all patients was 53.7 years, and most 
patients in the study (94.4%) were white, and 52.8% 
never smoked. More than 62% of all patients worked 
part-time or full time, and 8.9% of all patients were disa-
bled. Nearly 80% of all patients had private insurance of 
some kind, and the mean BMI for all patients was 31.5 
(±7.2). The median PsA duration since diagnosis was 
9 years, and 18 years for PsO. Over 62% of all patients 
reported a history of biologic use. For those patients 
currently reporting DMARD therapy, 17.9% were not 
on any DMARD therapy at enrolment, 29% were on 
methotrexate or another csDMARD and 53.1% were on 
biologics/tsDMARDs (table 1).
Patient demographic characteristics by degree of skin and 
joint involvement
At the time of enrolment, within each BSA group, 
higher BMIs were found among patients with higher 
CDAI, and the highest BMI (33.1±7.7) was observed 
in patients in the BSA >3%/CDAI medium-high 
subgroup. Significant differences were observed for 
current therapy among the six subgroups. Of note, 
those patients in the BSA 0%/CDAI low subgroup for 
skin disease severity and joint disease activity reported 
the highest use of any drug therapy with 63.7% using 
biologics/tsDMARDs (table 1).
All patient disease characteristics and patient-reported 
outcomes
Among all patients, 18.3% had enthesitis and a SPARCC 
score >0. The mean SPARCC score for those with 
enthesitis was 4.1±3.1. Nearly 45% of patients were in 
MDA. The mean BSA was 5.6 (±11.2), and the mean 
CDAI was 10.4 (±9.3). For the global assessment of PsO, 
25% were clear, 35.5% were almost clear, 24.4% had mild 
disease, 13.1% moderate disease and 2% severe disease. 
For the Disease Activity Score 28-joint count C-reactive 
protein, the majority of patients were in remission/low at 
57.9%, 30.4% were moderate and 11.7% were considered 
high. The mean Nail PsO visual analogue scale (VAS) 
score was 7.2 (±16.5), and the mean Health Assessment 
Questionnaire (HAQ) was 0.61 (±0.6). Patient-reported 
pain was 37.6 (±29.3), and patient-reported fatigue was 
40.2 (±29.1) (table 2).
Patient disease characteristics and patient-reported 
outcomes by degree of skin and joint involvement
Patients in the BSA >3%/CDAI moderate-high subgroup 
had the highest Nail PsO VAS with a median score of 17.5 
(±23.4). For all patients, the highest mean HAQ of 1.06 
(±0.7) was among patients in the BSA >3%/CDAI moder-
ate-high subgroup. As BSA increased, the HAQ scores in 
the moderate-high CDAI groups also increased. In those 
patients with enthesitis, the highest SPARCC score of 5.3 
(±3.1) was in the BSA 0%/CDAI moderate-high subgroup. 
Patient-reported pain (57.1±27.6) and patient-reported 
fatigue (54.0±28.2) are the highest among patients in the 
BSA >3%/CDAI moderate-high subgroup. Patients with 
PsA in the BSA 0%/low CDAI subgroup had the highest 
mean EuroQol Group 5-Dimensional Questionnaire 
scores (79.4±18.9) and a larger percentage (18.3%) of 
patients reported no morning stiffness (table 2).
The relationship between degree of skin and joint 
involvement
Table 3 displays the classification table of skin disease 
severity (BSA, 0%, >0% to 3%, >3%) by joint involvement 
(CDAI, low vs moderate-high). We observed a signifi-
cant (p<0.001) modest association (Cramer’s V=0.1639) 
between skin severity and joint involvement among all 
patients at the time of enrolment in the study. Patients 
with higher skin disease severity were over two times 
more likely to have higher joint involvement (OR 2.27, 
95% CI 1.71 to 3.01). Significant levels of association 
between skin disease severity and joint disease activity 
were also observed when stratified by therapy status at 
the time of enrolment. The level of association among 
patients on no DMARD therapy (Cramer’s V=0.2477) 
was higher compared with patients on csDMARDs only 
(Cramer’s V=0.1439) or biologics or tsDMARDs (Cram-
er’s V=0.1175). Specifically, patients on no DMARD 
therapy at enrolment with higher skin disease severity 
were 4.5 times more likely to have higher joint involve-
ment (OR 4.52, 95% CI 2.10 to 9.73) whereas patients 
on biologics or tsDMARDs at enrolment with higher 
4 Mease PJ, et al. RMD Open 2019;5:e000867. doi:10.1136/rmdopen-2018-000867
RMD Open
Ta
b
le
 1
 
P
at
ie
nt
 b
as
el
in
e 
d
em
og
ra
p
hi
c 
ch
ar
ac
te
ris
tic
s 
an
d
 h
is
to
ry
 o
f P
sA
 d
ru
g 
th
er
ap
y 
of
 a
ll 
p
at
ie
nt
s 
w
ith
 P
sA
 a
t 
tim
e 
of
 e
nr
ol
m
en
t
A
ll 
p
at
ie
nt
s
n=
15
42
P
at
ie
nt
s 
w
it
h 
P
sA
 c
at
eg
o
ri
se
d
 b
y 
sk
in
 a
nd
 jo
in
t 
d
is
ea
se
 a
ct
iv
it
y
0%
>
0%
 t
o
 3
%
>
3%
Lo
w
n=
25
8 
(1
6.
7)
M
/H
10
9 
(7
.1
)
Lo
w
44
7 
(2
9.
0)
M
/H
22
7 
(1
4.
7)
Lo
w
25
6 
(1
6.
6)
M
/H
24
5 
(1
5.
9)
P
 v
al
ue
A
ge
 (y
ea
rs
), 
n
15
22
25
7
10
9
44
2
22
0
25
3
24
1
<
0.
00
1
 
 M
ea
n 
(S
D
)
53
.7
±
13
.2
54
.5
±
12
.6
57
.9
±
10
.8
53
.5
±
13
.5
55
.3
±
13
.2
52
.1
±
13
.7
51
.8
±
13
.4
G
en
d
er
, n
15
31
25
6
10
9
44
5
22
5
25
2
24
4
<
0.
00
1
 
 n 
(%
) F
em
al
e
81
0 
(5
2.
9)
12
9 
(5
0.
4)
74
 (6
7.
9)
22
7 
(5
1.
0)
12
5 
(5
5.
6)
11
2 
(4
4.
4)
14
3 
(5
8.
6)
R
ac
e,
 n
14
91
25
2
10
5
43
0
21
7
24
9
23
8
0.
02
1
 
 W
hi
te
, n
 (%
)
14
08
 (9
4.
4)
24
0 
(9
5.
2)
99
 (9
4.
3)
41
5 
(9
6.
5)
20
6 
(9
4.
9)
23
4 
(9
4.
0)
21
4 
(8
9.
9)
In
su
ra
nc
e 
ty
p
e,
 n
 
 P
riv
at
e 
on
ly
 
 O
th
er
+
p
riv
at
e
 
 O
th
er
 
 N
on
e
15
14
11
18
 (7
3.
8)
11
3 
(7
.5
)
25
5 
(1
6.
8)
28
 (1
.9
)
25
5
19
4 
(7
6.
1)
17
 (6
.7
)
39
 (1
5.
3)
5 
(2
.0
)
10
7
69
 (6
4.
5)
12
 (1
1.
2)
22
 (2
0.
6)
4 
(3
.7
)
43
5
34
4 
(7
9.
1)
26
 (6
.0
)
59
 (1
3.
6)
6 
(1
.4
)
22
3
14
3 
(6
4.
1)
27
 (1
2.
1)
49
 (2
2.
0)
4 
(1
.8
)
25
2
20
0 
(7
9.
4)
15
 (6
.0
)
31
 (1
2.
3)
6 
(2
.4
)
24
2
16
8 
(6
9.
4)
16
 (6
.6
)
55
 (2
2.
7)
3 
(1
.2
)
<
0.
00
1
0.
03
7
0.
00
2
0.
61
7
S
m
ok
in
g 
st
at
us
, n
15
08
25
3
10
9
43
5
21
8
25
1
24
2
 
 N
ev
er
, n
 (%
 o
f N
)
79
6 
(5
2.
8)
14
3 
(5
6.
5)
67
 (6
1.
5)
23
2 
(5
3.
3)
11
9 
(5
4.
6)
12
3 
(4
9.
0)
11
2 
(4
6.
3)
0.
06
0
 
 Fo
rm
er
, n
 (%
 o
f N
)
 
 C
ur
re
nt
, n
 (%
 o
f N
)
54
4 
(3
6.
1)
16
8 
(1
1.
1)
95
 (3
7.
6)
15
 (5
.9
)
29
 (2
6.
6)
13
 (1
1.
9)
16
1 
(3
7.
0)
42
 (9
.7
)
76
 (3
4.
9)
23
 (1
0.
6)
95
 (3
7.
9)
33
 (1
3.
2)
88
 (3
6.
4)
42
 (1
7.
4)
0.
40
0
0.
00
2
B
M
I, 
n
14
72
25
1
10
4
41
5
21
5
25
0
23
7
0.
00
01
 
 M
ea
n 
(S
D
)
31
.5
±
7.
2
30
.4
±
6.
2
32
.2
±
8.
3
30
.7
±
6.
7
31
.6
±
7.
2
31
.7
±
7.
4
33
.1
±
7.
7
B
M
I c
at
eg
or
ie
s
 
 N
or
m
al
 (B
M
I <
25
)
 
 O
ve
rw
ei
gh
t 
(2
5≤
B
M
I<
30
)
 
 O
b
es
e 
(B
M
I ≥
30
)
 
 24
8 
(1
6.
9)
 
 44
5 
(3
0.
2)
 
 77
9 
(5
2.
9)
46
 (1
8.
3)
88
 (3
5.
1)
11
7 
(4
6.
6)
22
 (2
1.
1)
26
 (2
5.
0)
56
 (5
3.
9)
83
 (2
0.
0)
12
6 
(3
0.
4)
20
6 
(4
9.
6)
38
 (1
7.
7)
56
 (2
6.
1)
12
1 
(5
6.
3)
35
 (1
4.
0)
84
 (3
3.
6)
13
1 
(5
2.
4)
24
 (1
0.
1)
65
 (2
7.
4)
14
8 
(6
2.
5)
0.
01
6
0.
14
9
0.
00
9
P
sA
 d
is
ea
se
 d
ur
at
io
n 
(y
ea
rs
)
 
 
 Fr
om
 d
ia
gn
os
is
 d
at
e,
 n
14
85
22
3
13
0
36
9
28
4
21
7
26
2
0.
08
27
 
 M
ed
ia
n 
(IQ
R
)
9.
0 
(4
.0
, 1
6.
0)
10
.0
 (4
.0
, 1
8.
0)
8.
5 
(4
.0
, 1
9.
0)
8.
0 
(4
.0
, 1
5.
0)
8.
0 
(4
.0
, 1
5.
0)
10
.0
 (5
.0
, 1
8.
0)
9.
0 
(4
.0
, 1
6.
0)
P
sO
 d
is
ea
se
 d
ur
at
io
n 
(y
ea
rs
)
 
 
 Fr
om
 d
ia
gn
os
is
 d
at
e,
 n
92
3
12
6
43
29
1
12
5
18
4
15
4
0.
95
70
 
 M
ed
ia
n 
(IQ
R
)
18
.0
 (9
.0
, 2
8.
0)
18
.0
 (1
0.
0,
 2
8.
0)
16
.0
 (7
.0
, 3
1.
0)
17
.0
 (9
.0
, 2
6.
0)
16
.0
 (7
.0
, 3
2.
0)
19
.0
 (1
1.
0,
 2
8.
0)
17
.0
 (1
0.
0,
 2
9.
0)
W
or
k 
st
at
us
, n
15
24
25
7
10
8
44
4
22
2
25
2
24
1
 
 Fu
ll/
p
ar
t-
tim
e,
 n
 (%
 o
f N
)
 
 S
tu
d
en
t/
W
FH
, n
 (%
 o
f N
)
 
 R
et
ire
d
, n
 (%
 o
f N
)
 
 D
is
ab
le
d
, n
 (%
 o
f N
)
95
9 
(6
2.
9)
10
3 
(6
.8
)
32
6 
(2
1.
4)
13
6 
(8
.9
)
16
9 
(6
5.
8)
19
 (7
.4
)
60
 (2
3.
4)
9 
(3
.5
)
51
 (4
7.
2)
3 
(2
.8
)
36
 (3
3.
3)
18
 (1
6.
7)
30
7 
(6
9.
1)
29
 (6
.5
)
89
 (2
0.
1)
19
 (4
.3
)
11
7 
(5
2.
7)
15
 (6
.8
)
55
 (2
4.
8)
35
 (1
5.
8)
17
7 
(7
0.
2)
17
 (6
.8
)
44
 (1
7.
5)
14
 (5
.6
)
13
8 
(5
7.
3)
20
 (8
.3
)
42
 (1
7.
4)
41
 (1
7.
0)
<
0.
00
1
0.
57
5
0.
00
6
<
0.
00
1
C
on
tin
ue
d
5Mease PJ, et al. RMD Open 2019;5:e000867. doi:10.1136/rmdopen-2018-000867
Psoriatic arthritis
A
ll 
p
at
ie
nt
s
n=
15
42
P
at
ie
nt
s 
w
it
h 
P
sA
 c
at
eg
o
ri
se
d
 b
y 
sk
in
 a
nd
 jo
in
t 
d
is
ea
se
 a
ct
iv
it
y
0%
>
0%
 t
o
 3
%
>
3%
Lo
w
n=
25
8 
(1
6.
7)
M
/H
10
9 
(7
.1
)
Lo
w
44
7 
(2
9.
0)
M
/H
22
7 
(1
4.
7)
Lo
w
25
6 
(1
6.
6)
M
/H
24
5 
(1
5.
9)
P
 v
al
ue
P
rio
r 
th
er
ap
y
 
 
 H
x 
of
 p
rio
r 
b
io
lo
gi
c 
us
e
 
 
 A
ny
 b
io
lo
gi
c,
 n
 (%
)
96
6 
(6
2.
7)
17
7 
(6
8.
9)
70
 (6
4.
2)
28
6 
(6
4.
0)
13
2 
(5
8.
2)
16
1 
(6
2.
9)
14
0 
(5
7.
4)
0.
08
8
C
ur
re
nt
 t
he
ra
p
y
 
 
 C
ur
re
nt
 D
M
A
R
D
 t
he
ra
p
y
14
84
24
5
10
3
42
8
22
1
25
2
23
5
 
 N
ot
 o
n 
D
M
A
R
D
 t
he
ra
p
y
 
 26
6 
(1
7.
9)
29
 (1
1.
8)
13
 (1
2.
6)
54
 (1
2.
6)
61
 (2
7.
6)
36
 (1
4.
3)
73
 (3
1.
1)
<
0.
00
1
 
 M
TX
 o
r 
ot
he
r 
cs
D
M
A
R
D
s 
(n
o 
b
io
lo
gi
cs
) o
nl
y
43
0 
(2
9.
0)
60
 (2
4.
5)
30
 (2
9.
1)
13
4 
(3
1.
3)
68
 (3
0.
8)
71
 (2
8.
2)
67
 (2
8.
5)
0.
55
3
 
 B
io
lo
gi
cs
/t
sD
M
A
R
D
s
78
8 
(5
3.
1)
15
6 
(6
3.
7)
60
 (5
8.
3)
24
0 
(5
6.
1)
92
 (4
1.
6)
14
5 
(5
7.
5)
95
 (4
0.
4)
<
0.
00
1
P
 v
al
ue
 r
ep
re
se
nt
s 
co
m
p
ar
is
on
s 
b
et
w
ee
n 
C
D
A
I/
B
S
A
 s
ub
gr
ou
p
s 
an
d
 w
er
e 
an
al
ys
ed
 u
si
ng
 χ
2  
te
st
s,
 F
is
he
r’s
 e
xa
ct
 t
es
ts
, t
-t
es
ts
 o
r 
W
ilc
ox
on
-M
an
n-
W
hi
tn
ey
 t
es
ts
, a
s 
ap
p
ro
p
ria
te
. S
ki
n 
se
ve
rit
y 
b
y 
le
ve
ls
 o
f B
S
A
: 0
%
, >
0%
 t
o 
3%
 a
nd
 >
3%
; j
oi
nt
 a
ct
iv
ity
 b
y 
le
ve
ls
 o
f C
D
A
I: 
lo
w
 a
nd
 M
/H
=
m
od
er
at
e/
hi
gh
; B
M
I: 
b
as
ed
 o
n 
th
e 
C
D
C
 c
ut
-o
ffs
 fo
r 
no
rm
al
/u
nd
er
w
ei
gh
t 
(u
nd
er
 2
5)
; o
ve
rw
ei
gh
t 
(2
5.
0–
29
.9
); 
an
d
 o
b
es
e 
(3
0.
0 
an
d
 a
b
ov
e)
. F
or
 in
su
ra
nc
e,
 O
th
er
 in
cl
ud
es
 M
ed
ic
ar
e 
an
d
 M
ed
ic
ai
d
.
B
M
I, 
b
od
y 
m
as
s 
in
d
ex
; B
S
A
, b
od
y 
su
rf
ac
e 
ar
ea
; C
D
A
I, 
C
lin
ic
al
 D
is
ea
se
 A
ct
iv
ity
 In
d
ex
; C
D
C
, C
en
te
rs
 fo
r 
D
is
ea
se
 C
on
tr
ol
 a
nd
 P
re
ve
nt
io
n;
 D
M
A
R
D
, d
is
ea
se
-m
od
ify
in
g 
an
tir
he
um
at
ic
 d
ru
g;
 H
x,
 
hi
st
or
y;
 M
TX
, m
et
ho
tr
ex
at
e;
 P
sA
, p
so
ria
tic
 a
rt
hr
iti
s;
 W
FH
, w
or
k 
fr
om
 h
om
e;
 c
sD
M
A
R
D
, c
on
ve
nt
io
na
l s
yn
th
et
ic
 D
M
A
R
D
; t
sD
M
A
R
D
, t
ar
ge
te
d
 s
yn
th
et
ic
 D
M
A
R
D
.
Ta
b
le
 1
 
C
on
tin
ue
d
6 Mease PJ, et al. RMD Open 2019;5:e000867. doi:10.1136/rmdopen-2018-000867
RMD Open
Ta
b
le
 2
 
D
is
ea
se
 c
ha
ra
ct
er
is
tic
s 
an
d
 p
at
ie
nt
-r
ep
or
te
d
 o
ut
co
m
es
 o
f a
ll 
p
at
ie
nt
s 
w
ith
 P
sA
 a
t 
tim
e 
of
 e
nr
ol
m
en
t
A
ll 
p
at
ie
nt
s
P
at
ie
nt
s 
w
it
h 
P
sA
 c
at
eg
o
ri
se
d
 b
y 
sk
in
 a
nd
 jo
in
t 
ac
ti
vi
ty
P
 v
al
ue
0%
>
0%
 t
o
 3
%
>
3%
Lo
w
M
/H
Lo
w
M
/H
Lo
w
M
/H
E
nt
he
si
tis
, n
n 
(%
) w
ith
 S
PA
R
C
C
 
sc
or
e 
>
0
15
42
28
2 
(1
8.
3)
25
8
22
 (8
.5
)
10
9
23
 (2
1.
1)
44
7
61
 (1
3.
7)
22
7
79
 (3
4.
9)
25
6
18
 (7
.0
)
24
5
79
 (3
2.
2)
<
0.
00
1
S
PA
R
C
C
 s
co
re
 
(a
m
on
g 
th
os
e 
w
ith
 
en
th
es
iti
s)
 
 
 
 
 
 
 
0.
00
03
 
 M
ea
n 
(S
D
)
4.
1±
3.
1
2.
9±
2.
1
5.
3±
3.
1
3.
0±
2.
3
4.
4±
2.
8
3.
9±
2.
5
4.
8±
3.
8
 
 M
ed
ia
n 
(IQ
R
)
3.
0 
(2
.0
, 6
.0
)
2.
0 
(1
.0
, 4
.0
)
6.
0 
(3
.0
, 7
.0
)
2.
0 
(1
.0
, 4
.0
)
4.
0 
(2
.0
, 7
.0
)
3.
5 
(2
.0
, 6
.0
)
4.
0 
(2
.0
, 7
.0
)
D
ac
ty
lit
is
, n
15
42
25
8
10
9
44
7
22
7
25
6
24
5
<
0.
00
1
 
 n 
(%
) w
ith
 d
ac
ty
lit
is
 
co
un
t 
>
0
14
1 
(9
.1
)
8 
(3
.1
)
10
 (9
.2
)
27
 (6
.0
)
39
 (1
7.
2)
8 
(3
.1
)
49
 (2
0.
0)
D
ac
ty
lit
is
 c
ou
nt
 
(a
m
on
g 
th
os
e 
w
ith
 
d
ac
ty
lit
is
)
 
 
 
 
 
 
 
 
 M
ea
n 
(S
D
)
2.
2±
1.
8
1.
4±
0.
7
2.
4±
1.
8
1.
6±
1.
3
2.
4±
2.
0
1.
1±
0.
4
2.
7±
1.
8
0.
01
8
 
 M
ed
ia
n 
(IQ
R
)
2.
0 
(1
.0
, 3
.0
)
1.
0 
(1
.0
, 1
.5
)
1.
5 
(1
.0
, 4
.0
)
1.
0 
(1
.0
, 2
.0
)
2.
0 
(1
.0
, 3
.0
)
1.
0 
(1
.0
, 1
.0
)
2.
0 
(2
.0
, 4
.0
)
M
D
A
, n
14
26
24
5
10
3
41
6
20
3
23
8
22
1
<
0.
00
1
 
 n 
(%
)
63
9 
(4
4.
8)
18
0 
(7
3.
5)
22
 (2
1.
4)
29
6 
(7
1.
2)
33
 (1
6.
3)
10
2 
(4
2.
9)
6 
(2
.7
)
C
lin
ic
al
 g
lo
b
al
 
as
se
ss
m
en
t 
of
 
p
so
ria
si
s,
 n
15
23
25
5
10
7
44
0
22
5
25
5
24
1
 
 C
le
ar
, n
 (%
 o
f N
)
38
0 
(2
5.
0)
24
2 
(9
4.
9)
95
 (8
8.
8)
21
 (4
.8
)
14
 (6
.2
)
7 
(2
.8
)
1 
(0
.4
)
<
0.
00
1
 
 A
lm
os
t 
cl
ea
r, 
n 
(%
 
of
 N
)
54
0 
(3
5.
5)
13
 (5
.1
)
8 
(7
.5
)
29
8 
(6
7.
7)
11
8 
(5
2.
4)
61
 (2
3.
9)
42
 (1
7.
4)
<
0.
00
1
 
 M
ild
 d
is
ea
se
, n
 (%
 
of
 N
)
37
2 
(2
4.
4)
0 
(0
.0
)
4 
(3
.7
)
99
 (2
2.
5)
76
 (3
3.
8)
10
1 
(3
9.
6)
92
 (3
8.
2)
<
0.
00
1
 
 M
od
er
at
e 
d
is
ea
se
, 
n 
(%
 o
f N
)
20
0 
(1
3.
1)
0 
(0
.0
)
0 
(0
.0
)
22
 (5
.0
)
17
 (7
.6
)
75
 (2
9.
4)
86
 (3
5.
7)
<
0.
00
1
 
 S
ev
er
e 
d
is
ea
se
, n
 
(%
 o
f N
)
31
 (2
.0
)
0 
(0
.0
)
0 
(0
.0
)
0 
(0
.0
)
0 
(0
.0
)
11
 (4
.3
)
20
 (8
.3
)
<
0.
00
1
B
S
A
 (%
), 
n
15
42
25
8
10
9
44
7
22
7
25
6
24
5
<
0.
00
1
 
 M
ea
n 
(S
D
)
5.
6±
11
.2
0.
0±
0.
0
0.
0±
0.
0
1.
6±
0.
7
1.
6±
0.
8
14
.4
±
14
.8
16
.2
±
16
.6
 
 M
ed
ia
n 
(IQ
R
)
2.
0 
(1
.0
, 5
.0
)
0.
0 
(0
.0
, 0
.0
)
0.
0 
(0
.0
, 0
.0
)
1.
0 
(1
.0
, 2
.0
)
1.
0 
(1
.0
, 2
.0
)
9.
0 
(6
.0
, 1
6.
0)
10
.0
 (5
.0
, 1
8.
0)
C
on
tin
ue
d
7Mease PJ, et al. RMD Open 2019;5:e000867. doi:10.1136/rmdopen-2018-000867
Psoriatic arthritis
A
ll 
p
at
ie
nt
s
P
at
ie
nt
s 
w
it
h 
P
sA
 c
at
eg
o
ri
se
d
 b
y 
sk
in
 a
nd
 jo
in
t 
ac
ti
vi
ty
P
 v
al
ue
0%
>
0%
 t
o
 3
%
>
3%
Lo
w
M
/H
Lo
w
M
/H
Lo
w
M
/H
C
D
A
I, 
n
15
42
25
8
10
9
44
7
22
7
25
6
24
5
<
0.
00
1
 
 M
ea
n 
(S
D
)
10
.4
±
9.
3
4.
7±
3.
3
18
.6
±
8.
9
5.
0±
3.
2
18
.3
±
8.
2
5.
4±
3.
0
20
.5
±
10
.0
 
 M
ed
ia
n 
(IQ
R
)
8.
5 
(3
.5
, 1
4.
0)
4.
4 
(1
.7
, 8
.0
)
15
.5
 (1
2.
0,
 2
1.
0)
4.
8 
(2
.0
, 8
.0
)
16
.0
 (1
2.
5,
 2
2.
0)
5.
5 
(3
.0
, 8
.0
)
17
.7
 (1
3.
5,
 2
4.
5)
D
A
S
28
-C
R
P,
 n
85
6
16
5
73
23
0
12
2
13
5
13
1
<
0.
00
1
 
 M
ea
n 
(S
D
)
2.
6±
1.
1
1.
8±
0.
6
3.
5±
0.
9
2.
0±
0.
6
3.
7±
0.
9
2.
0±
0.
6
3.
9±
0.
9
 
 M
ed
ia
n 
(IQ
R
)
2.
4 
(1
.8
, 3
.3
)
1.
8 
(1
.3
, 2
.3
)
3.
4 
(3
.0
, 4
.1
)
2.
0 
(1
.6
, 2
.5
)
3.
5 
(3
.1
, 4
.1
)
2.
0 
(1
.6
, 2
.4
)
3.
8 
(3
.1
, 4
.4
)
D
A
S
28
-C
R
P,
 n
85
6
16
5
73
23
0
12
2
13
5
13
1
<
0.
00
1
 
 Lo
w
, n
 (%
 o
f N
)
49
6 
(5
7.
9)
15
6 
(9
4.
6)
13
 (1
7.
8)
19
3 
(8
3.
9)
11
 (9
.0
)
11
7 
(8
6.
7)
6 
(4
.6
)
<
0.
00
1
 
 M
od
er
at
e,
 n
 (%
 
of
 N
)
26
0 
(3
0.
4)
9 
(5
.6
)
42
 (5
7.
5)
37
 (1
6.
1)
78
 (6
3.
9)
18
 (1
3.
3)
76
 (5
8.
0)
<
0.
00
1
 
 H
ig
h,
 n
 (%
 o
f N
)
10
0 
(1
1.
7)
0 
(0
.0
)
18
 (2
4.
7)
0 
(0
.0
)
22
 (2
7.
1)
0 
(0
.0
0)
49
 (3
7.
4)
<
0.
00
1
N
ai
l i
nv
ol
ve
m
en
t,
 n
 
(%
)
67
7 
(4
3.
9)
66
 (2
5.
6)
36
 (3
3.
0)
17
4 
(3
8.
9)
11
5 
(5
0.
7)
12
7 
(4
9.
6)
15
9 
(6
4.
9)
<
0.
00
1
N
ai
l P
sO
 V
A
S
 (a
m
on
g 
th
os
e 
w
ith
 n
ai
l 
in
vo
lv
em
en
t) 
(0
–1
00
): 
m
ea
n 
(S
D
)
16
.2
±
21
.6
9.
9±
10
.3
19
.0
±
50
.1
10
.7
±
13
.1
13
.5
±
14
.2
16
.6
±
20
.0
25
.8
±
24
.3
<
0.
00
1
 
 M
ed
ia
n 
(IQ
R
)
8.
0 
(4
.0
, 2
0.
0)
5.
0 
(3
.0
, 1
5.
0)
5.
0 
(3
.0
, 1
5.
0)
5.
0 
(3
.0
, 1
3.
0)
7.
0 
(4
.0
, 2
0.
0)
7.
0 
(4
.0
, 2
1.
0)
20
.0
 (5
.0
, 4
0.
0)
H
A
Q
 (0
–3
), 
n
14
48
24
8
10
5
42
0
20
9
24
1
22
5
<
0.
00
1
 
 M
ea
n 
(S
D
)
0.
61
±
0.
6
0.
38
±
0.
5
0.
88
±
0.
7
0.
40
±
0.
5
0.
87
±
0.
7
0.
45
±
0.
5
1.
06
±
0.
7
 
 M
ed
ia
n 
(IQ
R
)
0.
38
 (0
.0
, 1
.0
)
0.
13
 (0
.0
, 0
.6
)
0.
75
 (0
.3
, 1
.5
)
0.
25
 (0
.0
, 0
.6
)
0.
88
 (0
.4
, 1
.4
)
0.
25
 (0
.0
, 0
.8
)
1.
00
 (0
.5
, 1
.5
)
P
at
ie
nt
 p
ai
n 
VA
S
 
(0
–1
00
), 
n
14
38
24
7
10
4
41
8
20
8
23
9
22
2
<
0.
00
1
 
 M
ea
n 
(S
D
)
37
.6
±
29
.3
26
.7
±
26
.0
45
.9
±
28
.9
28
.1
±
25
.9
50
.0
±
26
.6
32
.7
±
28
.2
57
.1
±
27
.6
 
 M
ed
ia
n 
(IQ
R
)
30
.0
 (1
0.
0,
 6
5.
0)
20
.0
 (5
.0
, 4
3.
0)
48
.0
 (1
7.
5,
 7
0.
0)
20
.0
 (5
.0
, 5
0.
0)
50
.0
 (3
0.
0,
 7
1.
5)
25
.0
 (1
0.
0,
 5
0.
0)
60
.0
 (3
5.
0,
 8
0.
0)
E
Q
5D
 (0
–1
), 
n
15
16
25
4
10
5
44
0
22
5
25
3
23
9
<
0.
00
1
 
 M
ea
n 
(S
D
)
72
.3
±
21
.1
79
.4
±
18
.9
64
.3
±
23
.8
77
.9
±
17
.5
66
.5
±
20
.7
76
.9
±
16
.9
58
.8
±
23
.4
 
 M
ed
ia
n 
(IQ
R
)
80
.0
 (6
0.
0,
 9
0.
0)
85
.0
 (7
3.
0,
 9
2.
0)
70
.0
 (5
0.
0,
 8
0.
0)
80
.0
 (7
0.
0,
 9
0.
0)
70
.0
 (5
0.
0,
 8
1.
0)
80
.0
 (7
0.
0,
 9
0.
0)
60
.0
 (4
0.
0,
 8
0.
0)
P
at
ie
nt
-r
ep
or
te
d
 
fa
tig
ue
(0
–1
00
), 
n
15
17
25
5
10
7
43
8
22
3
25
0
24
4
<
0.
00
1
 
 M
ea
n 
(S
D
)
40
.2
±
29
.1
31
.4
±
27
.2
45
.2
±
29
.4
33
.3
±
27
.1
49
.7
±
27
.8
37
.4
±
29
.1
54
.0
±
28
.2
Ta
b
le
 2
 
C
on
tin
ue
d
C
on
tin
ue
d
8 Mease PJ, et al. RMD Open 2019;5:e000867. doi:10.1136/rmdopen-2018-000867
RMD Open
A
ll 
p
at
ie
nt
s
P
at
ie
nt
s 
w
it
h 
P
sA
 c
at
eg
o
ri
se
d
 b
y 
sk
in
 a
nd
 jo
in
t 
ac
ti
vi
ty
P
 v
al
ue
0%
>
0%
 t
o
 3
%
>
3%
Lo
w
M
/H
Lo
w
M
/H
Lo
w
M
/H
 
 M
ed
ia
n 
(IQ
R
)
40
.0
(1
2.
0,
 6
5.
0)
25
.0
(8
.0
, 5
5.
0)
45
.0
(2
0.
0,
 7
0.
0)
25
.0
(1
0.
0,
 5
5.
0)
50
.0
(2
5.
0,
 7
5.
0)
30
.0
(1
0.
0,
 6
3.
0)
60
.0
(3
1.
0,
 7
5.
0)
M
or
ni
ng
 s
tif
fn
es
s,
 n
14
89
25
1
10
4
42
9
22
2
24
1
24
2
<
0.
00
1
 
 0 
ho
ur
, n
 (%
)
17
2 
(1
1.
6)
46
 (1
8.
3)
5 
(4
.8
)
67
 (1
5.
6)
13
 (5
.9
)
32
 (1
3.
3)
9 
(3
.7
)
P
 v
al
ue
 r
ep
re
se
nt
s 
co
m
p
ar
is
on
s 
b
et
w
ee
n 
C
D
A
I/
B
S
A
 s
ub
gr
ou
p
s 
an
d
 w
er
e 
an
al
ys
ed
 u
si
ng
 χ
2  
te
st
s,
 F
is
he
r’s
 e
xa
ct
 t
es
ts
, t
-t
es
ts
 o
r 
W
ilc
ox
on
-M
an
n-
W
hi
tn
ey
 t
es
ts
, a
s 
ap
p
ro
p
ria
te
. S
ki
n 
se
ve
rit
y 
b
y 
le
ve
ls
 o
f B
S
A
: 0
%
, >
0%
 t
o 
3%
 a
nd
 >
3%
; j
oi
nt
 a
ct
iv
ity
 b
y 
le
ve
ls
 o
f C
D
A
I: 
lo
w
 a
nd
 M
/H
.
B
S
A
, b
od
y 
su
rf
ac
e 
ar
ea
; C
D
A
I, 
C
lin
ic
al
 D
is
ea
se
 A
ct
iv
ity
 In
d
ex
; D
A
S
28
-C
R
P,
 D
is
ea
se
 A
ct
iv
ity
 S
co
re
 2
8-
jo
in
t 
co
un
t 
C
-r
ea
ct
iv
e 
p
ro
te
in
; E
Q
5D
, E
ur
oQ
ol
 G
ro
up
 5
-D
im
en
si
on
al
 Q
ue
st
io
nn
ai
re
; H
A
Q
, 
H
ea
lth
 A
ss
es
sm
en
t 
Q
ue
st
io
nn
ai
re
; M
D
A
, m
ild
 d
is
ea
se
 a
ct
iv
ity
; M
/H
, m
od
er
at
e/
hi
gh
; P
sA
, p
so
ria
tic
 a
rt
hr
iti
s;
 S
PA
R
C
C
, S
p
on
d
yl
oa
rt
hr
iti
s 
R
es
ea
rc
h 
C
on
so
rt
iu
m
 o
f C
an
ad
a;
 V
A
S
, v
is
ua
l a
na
lo
gu
e 
sc
al
e.
Ta
b
le
 2
 
C
on
tin
ue
d
skin disease severity were 1.7 times more likely to have 
higher joint involvement (OR 1.70, 95% CI 1.15 to 
2.52).
We observed a significant linear relationship between 
CDAI and BSA (linear regression of CDAI onto BSA 
is CDAI=9.48+0.16*BSA (95% CI 0.12 to 0.20 for BSA 
coefficient). When we evaluated the linear relation-
ship of CDAI and BSA accounting for a priori selected 
factors as potential effect modifiers, we observed signif-
icant interactions (evidence of effect modification) that 
showed this relationship was modified when accounting 
for other factors. Figure 1 provides a visual representa-
tion of the effect modification between CDAI and BSA 
by age, gender, work status, insurance, current therapy at 
enrolment and levels of HAQ, Nail VAS, MDA, dactylitis 
total, patient-reported pain and patient-reported fatigue. 
The red vertical line (y=0.16) represents the 0.16 unit 
increase in CDAI for every unit increase in BSA (from 
the linear regression of CDAI onto BSA). Deviations 
from this vertical line indicate how different levels of 
the identified factors modify the association between 
CDAI and BSA such that a stronger positive association 
is observed (point estimate of slope coefficient for BSA 
within the subgroup defined by covariate >0.16), weaker 
positive association (point estimate of slope coefficient 
for BSA within the subgroup defined by covariate <0.16) 
or negative association (point estimate of slope coeffi-
cient for BSA within the subgroup defined by covariate 
<0). The blue dotted vertical line (y=0) represents no 
association.
We observed a weaker relationship between CDAI 
(point estimate <0.16) and BSA when a patient appeared 
to have their disease under control. These patients were 
on some type of biologic or tsDMARD therapy, either 
younger (18–30 years) or older (>50 years), were in 
MDA, had no nail involvement (Nail VAS=0) or did not 
have dactylitis. There was an inverse relationship (point 
estimate of slope coefficient for BSA within the subgroup 
<0) between CDAI and BSA among patients with lowest 
reported pain (0–20) and fatigue (0–20), or had low 
levels of HAQ; however, the strength of the positive 
relationship between CDAI and BSA increased as pain, 
fatigue and HAQ levels increased, respectively. A weaker 
relationship (point estimate of slope coefficient for BSA 
within the subgroup <0.16) between CDAI and BSA was 
observed in males compared with females. A stronger 
relationship (point estimate of slope coefficient for BSA 
within the subgroup >0.16) was found among patients on 
Other (Medicare or Medicaid) or no insurance compared 
with patients on some type of private insurance (with or 
without Medicare or Medicaid). When we considered 
work status, we observed that for every unit increase in 
BSA, CDAI had, on average, a unit increase of >0.16 for 
students and those patients with PsA who work at home 
or were disabled, while the mean unit increase of CDAI 
was <0.16 for retirees.
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Table 3 The classification of skin disease severity (0%, >0% to 3%, >3%) by joint involvement (low vs moderate-high)
BSA
0% >0% to 3% >3% Total P value Cramer’s V
All patients
  CDAI  
  Low 258 447 256 961
  Moderate/high 109 227 245 581
  Total 367 674 501 1542 <0.001 0.1639
  OR (95% CI) Reference 1.20 (0.91, 1.58) 2.27 (1.71, 3.01)
No DMARD therapy at enrolment
  CDAI  
  Low 29 54 36 119
  Moderate/high 13 61 73 147
  Total 42 115 109 266 <0.001 0.2477
  OR (95% CI) Reference 2.52 (1.19, 5.33) 4.52 (2.10, 9.73)
csDMARDs only at enrolment
  CDAI  
  Low 60 134 71 265
  Moderate/high 30 68 67 165
  Total 90 202 138 430 0.012 0.1439
  OR (95% CI) Reference 1.01 (0.60, 1.72) 1.89 (1.09, 3.27)
Biologic or tsDMARDs 
at enrolment
 
  CDAI  
  Low 156 240 145 541
  Moderate/high 60 92 95 247
  Total 216 332 240 788 0.004 0.1175
  OR (95% CI) Reference 1.00 (0.68, 1.46) 1.70 (1.15, 2.52)
Drug therapy was missing for 58 patients. P value for χ2 test of association.
BSA, body surface area; CDAI, Clinical Disease Activity Index; DMARD, disease-modifying antirheumatic drug; OR, odds ratio; csDMARD, conventional 
synthetic DMARD; tsDMARD, targeted synthetic DMARD.
dIsCussIOn
Our objective was to compare patient characteristics at 
enrolment among patient groups stratified by degree of 
skin and joint involvement and to evaluate the relation-
ship between degree of skin and joint involvement in 
patients with PsA. Our study found substantial variation 
of skin and joint involvement in this cohort of patients 
with PsA, with some experiencing more articular versus 
skin disease and vice versa. Current therapy at enrolment 
was also significantly different across the skin and joint 
subgroups. It is important to note that most patients in 
the BSA >3%/CDAI moderate-high subgroup had worse 
clinical and patient-reported outcomes. Moreover, those 
patients in the BSA 0%/CDAI low subgroup reported 
the highest use of any drug therapy with 63.7% using 
biologics/tsDMARD. This may speak to the effectiveness 
of such therapies.
We also observed a statistically significant association 
between skin disease severity and joint involvement 
among all patients at the time of enrolment in the study. 
Furthermore, when we evaluated the linear relationship 
of CDAI and BSA, we found that some factors (ie, age, 
gender, insurance, work status, current therapy, HAQ, 
Nail VAS, MDA, dactylitis count, patient-reported pain 
and patient-reported fatigue) modified this relation-
ship. In evaluating the association between CDAI and 
BSA (categorised by severity level), we observed that the 
association was strongest among patients on no therapy, 
followed by patients on csDMARD therapy, versus 
biologic or tsDMARD therapy. However, when evaluating 
the linear association between CDAI and BSA (in their 
continuous form), the linear association was strongest 
within the csDMARD therapy group while the associa-
tion within the no therapy group is lower compared with 
the csDMARD group. We account for this difference 
due to the nature of the analysis (linear association of 
two continuous vs association between two categorical 
variables). In the evaluation of the linear association, the 
magnitude of the CDAI and BSA values (especially those 
in higher levels of activity) will affect the estimate of the 
association, whereas the effects of these larger in magni-
tude values are tempered when categorised into a high 
severity group.
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Figure 1 A display of the interactions of selected variables in the evaluation of the relationship between Clinical Disease 
Activity Index (CDAI) and body surface area (BSA). A display of the effect modifications by (A) age, (B) gender, (C) insurance, 
(D) work status, (E) current therapy, (F) HAQ, (G) Nail VAS, (H) MDA, (I) dactylitis total, (J) patient-reported pain and (K) patient-
reported fatigue on the linear relationship between CDAI and BSA. Closed circles represent point estimates; horizontal bars 
represent 95% confidence limits of average unit increase in CDAI for every 1 unit increase in BSA, stratified by level of each 
factor (ie, beta coefficients from the regression of CDAI on BSA including factor involved in the interaction). Red vertical line 
(y=0.16) represents the average increase in CDAI (0.16 increase) for every 1 unit increase in BSA (main effect from regression 
of CDAI onto BSA not accounting for other factors). The blue dotted vertical line (y=0) represents no association. csDMARD, 
conventional synthetic disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; MDA, minimal disease 
activity; tsDMARD, targeted synthetic DMARD; VAS, visual analogue scale; WFH, work from home.
Our study found a statistically significant association 
between joint disease activity and skin disease severity. 
Specifically, patients with higher skin disease severity 
(BSA >3%) were two times more likely to have higher 
joint involvement compared with those with a BSA=0%. 
These findings underscore that skin disease severity and 
joint disease activity are related and addressing both 
manifestations is essential in caring for patients with PsA.
Our findings of an increased likelihood of higher joint 
involvement with high skin severity suggest the need for 
rheumatologists and dermatologists to approach PsA 
patient care comprehensively. The relationship between 
skin and joint severity identified in our study indicates that 
in those patients who have a positive articular response to 
therapy, rheumatologists need to assess whether there is 
increasing skin involvement to ensure adequate control 
of both joint and skin symptoms. Likewise, when skin 
disease is well managed by dermatologists, but joint 
disease symptoms are persistent, rheumatologic consulta-
tion should be pursued. Although previous studies have 
reported an association only between joint activity and 
nail involvement,9 10 our study further showed the asso-
ciation between skin disease severity and joint disease 
activity was stronger in certain patient subgroups, namely 
those who were not in MDA, with higher Nail VAS severity, 
in patients who worked from home or were students, 
and who had higher HAQ and other patient-reported 
outcome scores. Because of the exploratory nature of 
our study, more investigation is needed to confirm these 
observations.
Some limitations should be noted. In this study, we 
used CDAI (based on 28 tender and swollen joint counts) 
to define joint disease activity. Although initially derived 
for rheumatoid arthritis, CDAI has been used to measure 
joint activity in patients with PsA. However, a limita-
tion of using CDAI is that it does not capture articular 
involvement of feet and ankle which is frequent in PsA. 
The Disease Activity in Psoriatic Arthritis (DAPSA) score 
includes 66/68 joint counts, C-reactive protein (CRP) as 
well as patient pain assessment. By using CDAI instead of 
DAPSA, we were able to achieve a larger sample size since 
CRP is not a required reporting measure in the Corrona 
Registry and not available for all patients. The cDAPSA 
score (DAPSA with the removal of CRP) includes patient 
pain assessment, and if we used cDAPSA, another consid-
eration, we could not have evaluated the modification of 
the association between joint activity and skin severity by 
patient pain, a goal of our study. Moreover, we evaluated 
the correlation between CDAI and cDAPSA and observed 
a high correlation (0.78) between these two disease activity 
measures in our study. Misclassification due to recall bias 
is a potential limitation since the registry is not based on 
an inception cohort and patients could enter the study at 
any time during the course of their disease. The registry 
data are from a US-based registry, and the results may 
not be generalisable to populations residing outside the 
USA. In our study, the majority of patients (94.4%) were 
white, and thus the results may not be applicable to other 
racial backgrounds. However, the strengths of this study 
include the ability to identify a sufficiently large cohort 
of patients with PsA to characterise the relationship 
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between skin disease severity and joint disease activity, as 
well as to identify patient characteristics that modify that 
relationship.
Our findings demonstrate that skin disease severity is 
modestly correlated with joint disease activity, the rela-
tionship is affected by several patient and disease factors 
and those patients with higher skin disease severity are 
two times more likely to have higher joint involvement. 
Understanding the association between skin and joint 
involvement among patients with PsA emphasises the 
need for providers (specifically rheumatologists and 
dermatologists) to consider both skin disease severity and 
joint disease activity in the treatment of these patients. 
Further investigation of the association will help define 
gaps in current therapy regimens, such as an inherent 
tendency to focus on just one of the clinical domains 
of the disease (ie, skin or joint disease), not both; and 
address the clinical inertia by both providers and patients 
as it relates to the level of baseline expectations and to 
the satisfaction with treatment. Studying these differ-
ences will help us understand to what extent in the real 
world skin severity and joint activity correlate.
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